Physician profile
David L Smith
NPI 1659370104
$3,363.46
in general payments reported to CMS, 2019-2025
27 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $241 · 2021: $366 · 2022: $551 · 2023: $893 · 2024: $891 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $701.11 | 2019-2025 | |
| Amgen INC. | $389.72 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $355.22 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $255.08 | 2021-2024 | Verquvo |
| Pfizer INC. | $254.80 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $219.76 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $154.70 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $150.81 | 2019-2024 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $127.40 | 2022-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.43 | 2022-2024 | Jardiance |
| Boston Scientific Corporation | $110.40 | 2023-2024 | Watchman Access System, Watchman Flx |
| Sanofi-Aventis U.S. LLC | $60.14 | 2019-2023 | |
| Daiichi Sankyo INC. | $52.44 | 2023-2024 | Injectafer |
| Novo Nordisk INC | $51.34 | 2023-2024 | Rybelsus, Ozempic |
| Dentsply Ih Ab | $46.73 | 2023 | Lofric |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.29 | 2023-2025 | Lifevest |
| Kiniksa Pharmaceuticals, Ltd. | $42.27 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $40.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.65 | 2019-2020 | |
| Atricure, INC. | $30.41 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.12 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.53 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $21.64 | 2022 | |
| Inspire Medical Systems, INC. | $20.45 | 2024 | Inspire |
| Vital Connect, INC | $16.82 | 2023 | Vitalpatch Rtm |
| Kowa Pharmaceuticals America, INC. | $13.89 | 2021 | |
| Esperion Therapeutics, INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.